Biosimilar Naming Dilemma: If FDA Requires Suffixes, Do Reference Products Need Them, Too?
Executive Summary
If agency sticks with suffix approach it followed for Zarxio’s nonproprietary name it will have to figure out how broadly to apply that policy.